All Categories
Survival in Uncertain Times
 | Like so many seasoned industry professionals, we eagerly seek thought leader perspectives — on the current biopharma industry landscape; the investment strategies purported to be in play; and (of course) the likely true impact of the Inflation Reduction Act in both the near- and mid-term. As leaders in our own domains, it is essential that we hear… Read the full article… |
The Importance of a Commercialization Mindset
 | We write and speak a great deal about commercialization. It’s central to the work of our clients and, therefore, to ours as well. And so, in a recent panel, we brought together three experts from The NemetzGroup — Colleen Moore, Liz Tufo, and Tracey Sacco — to share their perspectives on the topic. Over the… Read the full article… |
Professionalism Still Matters
 | Sadly, another summer is coming to a close. If you have school-aged kids at home, you are undoubtedly already taking steps to shake them out of summer mode and get them ready for the new school year with its firm schedule and structure. For many of us working adults, however, the lines are not so… Read the full article… |
Be Bold, Be Empowered
 | Today’s e-conversation is about leadership. More specifically, it’s about what your leaders are really thinking. Coming up the ranks in various roles, I remember feeling frustrated at times when leadership would not “decide” or “give direction.” We were all working so hard; we often felt stymied by a perception that leadership was not “plugged in”… Read the full article… |
Optimize Your Congress Planning
 | Regardless of your company or drug development stage, congress events are critical undertakings; they represent both a substantial opportunity and a significant investment of time and resources. These events provide an occasion to engage with a wide range of HCPs (including KOLs) to introduce new products, present data, gather insights, and more. Depending on your… Read the full article… |
Communicating Without a Communications Leader
 | Many of our clients are emerging companies striving towards their first clinical development program in anticipation of delivering on a promise to the patients they hope to serve. In most of these companies, leadership is appropriately focused on advancing the science and developing a “reason to believe” for both internal and external stakeholders (investigators, potential… Read the full article… |
It’s Not All About the Numbers
 | What is the difference between strategic thinking in quantifying the future and Excel gymnastics? This was a distinction I needed to learn in my early years of marketing and, more specifically, market research. Often, I possessed a rich bevy of insights from primary market research (think green and white-striped cross-tabulations on pin-feed computer paper), together… Read the full article… |
Appreciation for Interconnectedness
 | It was precisely two years ago this month — March 2020 — when I wrote the first sentences of issue #30 of this e-conversation. At the time, I acknowledged the WHO’s declaration that COVID-19 had reached the threshold of a global pandemic. The remainder of that issue was about how to be productive working remotely.… Read the full article… |
Finding Partners: Standing Out in a Field of Many
 | When biopharma executives or business development leaders think about developing their “partnering story,” the focus is often on the innovation. That’s understandable. These are science-based organizations, and without question, the innovation is fundamental to the work. However, paying too much attention to the science at the expense of other aspects of the opportunity can lead… Read the full article… |
Gaining Participation in Clinical Trials
 | When it comes to patient recruitment and retention for clinical trials, the bottom line is simply this: It is important and challenging in all scenarios… the difference is in how significant the focus and effort will need to be. As this article suggests, identifying, engaging, and retaining appropriate patients for clinical trials can be extremely… Read the full article… |